Novo Nordisk ADR [NVO] stock prices are down -1.26% to $131.60 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The NVO shares have lost -2.82% over the last week, with a monthly amount drifted -7.51%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Novo Nordisk ADR [NYSE: NVO] stock has seen the most recent analyst activity on May 30, 2024, when Goldman initiated its Buy rating and assigned the stock a price target of $156. Previously, BMO Capital Markets started tracking the stock with Outperform rating on April 12, 2024, and set its price target to $163. On January 23, 2024, Morgan Stanley initiated with a Overweight rating and assigned a price target of $120 on the stock. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $120 as its price target on December 01, 2023. Argus started tracking with a Buy rating for this stock on October 02, 2023, and assigned it a price target of $110. In a note dated July 14, 2023, HSBC Securities initiated an Buy rating.
The stock price of Novo Nordisk ADR [NVO] has been fluctuating between $77.96 and $148.15 over the past year. Currently, Wall Street analysts expect the stock to reach $159.67 within the next 12 months. Novo Nordisk ADR [NYSE: NVO] shares were valued at $131.60 at the most recent close of the market. An investor can expect a potential return of 21.33% based on the average NVO price forecast.
Analyzing the NVO fundamentals
The Novo Nordisk ADR [NYSE:NVO] reported sales of 35.52B for trailing twelve months, representing a surge of 23.66%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at 0.45%, Pretax Profit Margin comes in at 0.46%, and Net Profit Margin reading is 0.37%. To continue investigating profitability, this company’s Return on Assets is posted at 0.3, Equity is 0.92 and Total Capital is 0.82. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 130.71 points at the first support level, and at 129.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 132.69, and for the 2nd resistance point, it is at 133.79.
Ratios To Look Out For
It’s worth pointing out that Novo Nordisk ADR [NYSE:NVO]’s Current Ratio is 0.70. As well, the Quick Ratio is 0.50, while the Cash Ratio is 0.04. Considering the valuation of this stock, the price to sales ratio is 12.37, the price to book ratio is 40.97 and price to earnings (TTM) ratio is 45.44.
